Target ALS – In Vivo Target Validation
Ends on 24 March 2025
Target ALS provides support for in vivo proof-of-concept for promising therapeutics in mouse models of ALS. We have partnered with the contract research organization Biospective to enable evaluation of novel therapeutics for target engagement and disease-modifying potential in ALS. Test articles – small molecules, biologics, gene therapy, or antisense oligonucleotides – are provided by the investigator. Results from these studies have the potential to catapult ALS drug candidates from preclinical to clinical pipelines, accelerating development of novel therapeutics.
All proposals are reviewed by the Target ALS Independent Review Committee.